Skip to main content

Advertisement

SpringerLink
Log in

Screening and Identification of Marburg Virus Entry Inhibitors Using Approved Drugs

  • LETTER
  • Published:
Virologica Sinica

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  • Bai JPF, Hsu CW (2018) Drug repurposing for Ebola virus disease: principles of consideration and the animal rule. J Pharm Sci 108:798–806

    Article  Google Scholar 

  • Bixler SL, Bocan TM, Wells J, Wetzel KS, Van Tongeren SA, Dong L, Garza NL, Donnelly G, Cazares LH, Nuss J, Soloveva V, Koistinen KA, Welch L, Epstein C, Liang LF, Giesing D, Lenk R, Bavari S, Warren TK (2017) Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus. Antivir Res 151:97–104

    Article  Google Scholar 

  • Brauburger K, Hume AJ, Muhlberger E, Olejnik J (2012) Forty-five years of Marburg virus research. Viruses 4:1878–1927

    Article  Google Scholar 

  • Cross RW, Mire CE, Feldmann H, Geisbert TW (2018) Post-exposure treatments for Ebola and Marburg virus infections. Nat Rev Drug Discov 17:413–434

    Article  CAS  Google Scholar 

  • Flyak AI, Ilinykh PA, Murin CD, Garron T, Shen X, Fusco ML, Hashiguchi T, Bornholdt ZA, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Ward AB, Saphire EO, Bukreyev A, Crowe JE Jr (2015) Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160:893–903

    Article  CAS  Google Scholar 

  • Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, Doranz BJ, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Saphire EO, Ward AB, Bukreyev A, Crowe JE Jr (2016) Cross-reactive and potent neutralizing antibody responses in human survivors of natural Ebola virus infection. Cell 164:392–405

    Article  CAS  Google Scholar 

  • Kouznetsova J, Sun W, Martinez-Romero C, Tawa G, Shinn P, Chen CZ, Schimmer A, Sanderson P, McKew JC, Zheng W, Garcia-Sastre A (2014) Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. Emerg Microbes Infect 3:e84

    Article  CAS  Google Scholar 

  • Leffel EK, Reed DS (2004) Marburg and Ebola viruses as aerosol threats. Biosecur Bioterror 2:186–191

    Article  Google Scholar 

  • Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA, Kolokoltsov AA, Carrion R Jr, Patterson JL, Bavari S, Panchal RG, Warren TK, Wells JB, Moos WH, Burke RL, Tanga MJ (2013) A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS ONE 8:e60579

    Article  CAS  Google Scholar 

  • Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, Kolokoltsov A, Davey R, Manger ID, Gilfillan L, Bavari S, Tanga MJ (2015) Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis 1:317–326

    Article  CAS  Google Scholar 

  • Marzi A, Banadyga L, Haddock E, Thomas T, Shen K, Horne EJ, Scott DP, Feldmann H, Ebihara H (2016) A hamster model for Marburg virus infection accurately recapitulates Marburg hemorrhagic fever. Sci Rep 6:39214

    Article  CAS  Google Scholar 

  • Wang J, Cheng H, Ratia K, Varhegyi E, Hendrickson WG, Li J, Rong L (2014) A comparative high-throughput screening protocol to identify entry inhibitors of enveloped viruses. J Biomol Screen 19:100–107

    Article  CAS  Google Scholar 

  • Zhang L, Li Q, Liu Q, Huang W, Nie J, Wang Y (2017) A bioluminescent imaging mouse model for Marburg virus based on a pseudovirus system. Hum Vaccin Immunother 13:1811–1817

    Article  Google Scholar 

Download references

Acknowledgements

We are grateful to Zongge Zhao and Lihua Xie from the Institute for Reference Standards and Standardization, National Institutes for Food and Drug Control, for providing the compounds. This work was supported by the National Key Research and Development Plan of China (Grant No. 2016YFC1200904). The funding bodies had no role in the study design, data collection or analysis, decision to publish, or preparation of the manuscript.

Author information

Author notes

  1. Li Zhang and Shan Lei have contributed equally to this work.

Authors and Affiliations

  1. Division of HIV/AIDS and Sexually-transmitted Virus Vaccines, National Institutes for Food and Drug Control, Beijing, 102629, China

    Li Zhang, Shan Lei, Hui Xie, Qianqian Li, Shuo Liu, Qiang Liu, Weijin Huang & Youchun Wang

  2. Institute for Reference Standards and Standardization, National Institutes for Food and Drug Control, Beijing, 102629, China

    Xinyue Xiao

Authors
  1. Li Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shan Lei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hui Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qianqian Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shuo Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qiang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Weijin Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xinyue Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Youchun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Youchun Wang.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest.

Animal and Human Rights Statement

All institutional and national guidelines for the care and use of laboratory animals were followed.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 519 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, L., Lei, S., Xie, H. et al. Screening and Identification of Marburg Virus Entry Inhibitors Using Approved Drugs. Virol. Sin. 35, 235–239 (2020). https://doi.org/10.1007/s12250-019-00184-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12250-019-00184-3

Search

Navigation